Apyx Medical Corp (APYX) stock
APYXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/3035% above fair value
$2.89−0.11 (-3.67%)
Close on Nov 12, 2026Market cap $121.74MP/E –Yield –
Apyx Medical r&d expenses
Research and development expenses are spending on new products and technology.
Apyx Medical's R&D Expenses for the twelve months ending Sep 30, 2026 was $3.35M, down 5.5% year over year. For fiscal 2025 it was $3.37M, down 33.6% from the year before. Over ten years it grew 4.6% a year on average. The highest annual figure on record is $5.44M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.37M | -33.6% |
| FY2024 | Dec 31, 2024 | $5.08M | -6.6% |
| FY2023 | Dec 31, 2023 | $5.44M | +19.7% |
| FY2022 | Dec 31, 2022 | $4.54M | +5.2% |
| FY2021 | Dec 31, 2021 | $4.32M | +10.2% |
| FY2020 | Dec 31, 2020 | $3.92M | +5.1% |
| FY2019 | Dec 31, 2019 | $3.73M | +46.4% |
| FY2018 | Dec 31, 2018 | $2.55M | +31.3% |
| FY2017 | Dec 31, 2017 | $1.94M | +87.9% |
| FY2016 | Dec 31, 2016 | $1.03M | -52.2% |
| FY2015 | Dec 31, 2015 | $2.16M | +52.5% |
| FY2014 | Dec 31, 2014 | $1.42M | +12.4% |
| FY2013 | Dec 31, 2013 | $1.26M | -5.2% |
| FY2012 | Dec 31, 2012 | $1.33M | +11.0% |
| FY2011 | Dec 31, 2011 | $1.20M | -35.4% |
| FY2010 | Dec 31, 2010 | $1.85M | -11.0% |
| FY2009 | Dec 31, 2009 | $2.08M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $849.00K | +6.0% |
| Q2 FY2026 | Jun 30, 2026 | $793.00K | -3.8% |
| Q1 FY2026 | Mar 31, 2026 | $765.00K | -4.9% |
| Q4 FY2025 | Dec 31, 2025 | $944.00K | -15.5% |
| Q3 FY2025 | Sep 30, 2025 | $801.00K | -29.9% |
| Q2 FY2025 | Jun 30, 2025 | $824.00K | -42.1% |
| Q1 FY2025 | Mar 31, 2025 | $804.00K | -42.4% |
| Q4 FY2024 | Dec 31, 2024 | $1.12M | -20.4% |
| Q3 FY2024 | Sep 30, 2024 | $1.14M | -18.9% |
| Q2 FY2024 | Jun 30, 2024 | $1.42M | +4.9% |
| Q1 FY2024 | Mar 31, 2024 | $1.40M | +9.9% |
| Q4 FY2023 | Dec 31, 2023 | $1.40M | +11.8% |
| Q3 FY2023 | Sep 30, 2023 | $1.41M | +32.8% |
| Q2 FY2023 | Jun 30, 2023 | $1.36M | +26.8% |
| Q1 FY2023 | Mar 31, 2023 | $1.27M | +9.8% |
| Q4 FY2022 | Dec 31, 2022 | $1.26M | +32.5% |
| Q3 FY2022 | Sep 30, 2022 | $1.06M | -9.7% |
| Q2 FY2022 | Jun 30, 2022 | $1.07M | -1.3% |
| Q1 FY2022 | Mar 31, 2022 | $1.16M | +3.9% |
| Q4 FY2021 | Dec 31, 2021 | $947.00K | +3.2% |
| Q3 FY2021 | Sep 30, 2021 | $1.18M | +12.2% |
| Q2 FY2021 | Jun 30, 2021 | $1.08M | +11.2% |
| Q1 FY2021 | Mar 31, 2021 | $1.12M | +13.8% |
| Q4 FY2020 | Dec 31, 2020 | $918.00K | -16.3% |
| Q3 FY2020 | Sep 30, 2020 | $1.05M | +3.1% |
| Q2 FY2020 | Jun 30, 2020 | $975.00K | +9.8% |
| Q1 FY2020 | Mar 31, 2020 | $980.00K | +34.2% |
| Q4 FY2019 | Dec 31, 2019 | $1.10M | +66.5% |
| Q3 FY2019 | Sep 30, 2019 | $1.02M | +65.7% |
| Q2 FY2019 | Jun 30, 2019 | $888.00K | +16.4% |
| Q1 FY2019 | Mar 31, 2019 | $730.00K | +42.0% |
| Q4 FY2018 | Dec 31, 2018 | $659.00K | +93.3% |
| Q3 FY2018 | Sep 30, 2018 | $613.00K | +25.9% |
| Q2 FY2018 | Jun 30, 2018 | $763.00K | +9.6% |
| Q1 FY2018 | Mar 31, 2018 | $514.00K | -27.5% |
| Q4 FY2017 | Dec 31, 2017 | $341.00K | -49.6% |
| Q3 FY2017 | Sep 30, 2017 | $487.00K | – |
| Q2 FY2017 | Jun 30, 2017 | $696.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $709.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $677.00K | – |
See a number that looks wrong?